Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma

International Journal of Cancer

Volumn 111, Issue 5, 2004, Pages 741-745

  Mocellin, Simone ^a   Del Fiore, Paolo ^a   Guarnieri, Laura ^a   Scalerta, Romano ^a   Foletto, Mirto ^a   Chiarion, Vanna ^a   Pilati, Pierluigi ^a   Nitti, Donato ^a   Lise, Mario ^a   Rossi, Carlo R ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adjuvant therapy; Circulating tumor cell; Cutaneous melanoma; Disease recurrence; Prognosis

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; MONOPHENOL MONOOXYGENASE; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DNA SYNTHESIS; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; TUMOR CELL; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM CIRCULATING CELLS; NEOPLASM PROTEINS; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 4043061534     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20347     Document Type: Article

References (40)

1. Mocellin S, Rossi CR, Lise M, Marincola FM. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother 2002;51:583-95.
2. Pawlik TM, Sondak VK. Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 2003;45:245-64.
3. Terando A, Sabel MS, Sondak VK. Melanoma: adjuvant therapy and other treatment options. Curr Treat Options Oncol 2003;4:187-99.
4. Cascinelli N, Santinami M, Maurichi A, Patuzzo R, Pennacchioli E. World Health Organization experience in the treatment of melanoma. Surg Clin North Am 2003;83:405-16.
5. Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V. Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 2003;21:2609-15.
6. Seiter S, Rappl G, Tilgen W, Ugurel S, Reinhold U. Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR. Recent Results Cancer Res 2001;158:105-12.
7. Bockmann B, Grill HJ, Giesing M. Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol Eng 2001;17:95-111.
8. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 1996;78:10-6.
9. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121:823-38.
10. Maslak P. Clinical applications of molecular monitoring in leukemia. Curr Hematol Rep 2003;2:43-8.
11. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24.
12. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003;3:589-96.
13. Chambers AF. The metastatic process: basic research and clinical implications. Oncol Res 1999;11:161-8.
14. Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, Napolitano M, Caraco C, Mozzillo N, Melucci MT, Cossu A, Tanda F, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003;21:767-73.
15. Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001;137:325-30.
16. Schittek B, Blaheta HJ, Ellwanger U, Garbe C. Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. Recent Results Cancer Res 2001;158:93-104.
17. Max N, Keilholz U. Minimal residual disease in melanoma. Semin Surg Oncol 2001;20:319-28.
18. Feezor RJ, Copeland EM 3rd, Hochwald SN. Significance of micrometastases in colorectal cancer. Ann Surg Oncol 2002;9:944-53.
19. Tsavellas G, Patel H, Allen-Mersh TG. Detection and clinical significance of occult tumour cells in colorectal cancer. Br J Surg 2001;88:1307-20.
20. Baker M, Gillanders WE, Mikhitarian K, Mitas M, Cole DJ. The molecular detection of micrometastatic breast cancer. Am J Surg 2003;186:351-8.
21. Jiang WG, Martin TA, Mansel RE. Molecular detection of micrometastasis in breast cancer. Crit Rev Oncol Hematol 2002;43:13-31.
22. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
23. Rossi CR, Seno A, Vecchiato A, Foletto M, Tregnaghi A, De Candia A, Rubaltelli L, Montesco C, Lise M. The impact of ultrasound scanning in the staging and follow-up of patients with clinical stage I cutaneous melanoma. Eur J Cancer 1997;33:200-3.
24. Rossi CR, Scagnet B, Vecchiato A, Mocellin S, Pilati PL, Foletto M, Zavagno G, Casara D, Montesco MC, Tregnaghi A, Rubaltelli L, Lise M. Sentinel node biopsy and ultrasound scanning in cutaneous melanoma: clinical and technical considerations. Eur J Cancer 2000;36:895-900.
25. Brossart P, Keilholz U, Scheibenbogen C, Mohler T, Willhauck M, Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother 1994;15:38-41.
26. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-9.
27. Berking C, Schlupen EM, Schrader A, Atzpodien J, Volkenandt M. Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch Dermatol Res 1999;291:479-84.
28. Gogas H, Kefala G, Bafaloukos D, Frangia K, Polyzos A, Pectasides D, Tsoutsos D, Panagiotou P, Ioannovich J, Loukopoulos D. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer 2002;87:181-6.
29. Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quinto L, Fontanillas M, Reguart N, Domingo-Domenech JM, Montagut C, Estape J, Gascon P. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002;20:4032-9.
30. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, Morton DL. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000;60:2253-7.
31. Baldi A, Dragonetti E, Battista T, Groeger AM, Esposito V, Baldi G, Santini D. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients. Anticancer Res 2000;20:3923-8.
32. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003;97:1737-45.
33. Ghossein RA, Bhattacharya S, Coit DG. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of melanoma-related transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? Recent Results Cancer Res 2001;158:63-77.
34. Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003;9:1497-502.
35. Brownbridge GG, Gold J, Edward M, MacKie RM. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001;144:279-87.
36. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999;17:2562-71.
37. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
38. Schmidt H, Sorensen BS, von der Maase H, Bang C, Agger R, Hokland M, Nexo E. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma. Melanoma Res 2002;12:585-92.
39. Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, Hoon DS. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res 2001;158:78-92.
40. Max N, Wolf K, Spike B, Thiel E, Keilholz U. Nested quantitative real time PCR for detection of occult tumor cells. Recent Results Cancer Res 2001;158:25-31.